ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021
- To present recent progress of clinical pipeline at the H.C. Wainwright Bioconnect Conference
- Will participate in LifeSci Advisors’ 10th Annual LifeSci Advisors Corporate Access Event 2021
- Will participate in Edison’s Open House – Global Healthcare 2021
- Will present and participate at ACCESS CHINA Forum @JPM Week 2021
- All virtual events during three consecutive weeks in January
MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, January 4th, 2021 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that its management will update on corporate progress at several events during the first three weeks of January 2021.
Dr. Carlos Buesa, Oryzon’s CEO, will present a corporate update at the H.C.Wainwright Bioconnect Conference, which will be held virtually on January 11-14. Oryzon’s corporate presentation will be available to conference attendees from January 11 06:00 am ET (On-Demand Session). For more info about this conference, please visit https://hcwevents.com/bioconnect/
Oryzon will also participate at the Annual LifeSci Advisors Corporate Access Event that is scheduled from January 6 till January 11 where its CEO and CSO, Dr. Torsten Hoffmann, will hold meetings with pharmaceutical companies, institutional investors, analysts and other members of the biotech community. During this event the CEO will participate in a panel of five European Companies entitled "Separating the Wheat from the Chaff: Most Promising Novel Oncology Targets in Development" that will be moderated by John Hodgson, an established scientific journalist and former editor of Nature Biotechnology, that will be held on Thursday January 7 at 08.00 am ET. To register to listen to the panel or to request a meeting with the CEO and CSO, visit: http://lifesci.events/LifeSci2021
Oryzon will also participate at the Edison’s Open House – Global Healthcare 2021 from January 26 till January 28, where the CEO will give a company overview and participate in a fireside-chat that will be moderated by Vivianne Parry, an established BBC scientific journalist and member of Genomics England. For more info on this event, please visit https://www.lsegissuerservices.com/spark/edison-open-house-global-healthcare-2021
Oryzon will also take part in the ACCESS CHINA Forum organized by the Chinese Investment Bank YAFO Capital from January 4 till January 22 where Directors of the Company will hold meetings with Chinese pharmaceutical companies, and Chinese institutional investors.
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds, vafidemstat and iadademstat, in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has offices in Spain and the United States. Oryzon is one of the most liquid biotech stocks in Europe with +90 M shares negotiated in 2020 (ORY:SM / ORY.MC / ORYZF US OTC mkt). The company had a +25% stock performance in 2020 and its cash runway is expected to extend till 1Q2023. For more information, visit www.oryzon.com
Iadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (See Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A first Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi. Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), medulloblastoma and others. Oryzon is conducting two Phase IIa clinical trials of iadademstat in combination; the first one in combination with azacitidine in elderly AML patients (ALICE study) and the second one in combination with platinum/etoposide in second line SCLC patients (CLEPSIDRA study). In both studies, preliminary clinical results have been reported.
Vafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer’s disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed a Phase IIa clinical trial in aggressiveness in patients with different psychiatric disorders (REIMAGINE) and in aggressive/agitated patients with moderate or severe AD (REIMAGINE-AD), with positive preliminary clinical results reported. A Phase IIb trial in borderline personality disorder (PORTICO) has been recently authorized. Additional Phase IIa clinical trials with vafidemstat are ongoing in patients with Mild to Moderate AD (ETHERAL), where a significant reduction of the inflammatory biomarker YKL40 has been observed after 6 months of treatment, and in Relapse-Remitting and Secondary Progressive MS (SATEEN). Vafidemstat is also being explored in a Phase II in severe Covid-19 patients assessing the capability of the drug to prevent ARDS, one of the most severe complications of the viral infection.
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon’s securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.